secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001558370-25-004154
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech posts FY2024 net loss of $55.9M; Checkpoint to be acquired by Sun Pharma
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders of $55.9M ($2.69/sh) vs $68.7M ($8.47/sh) in FY2023; net revenue $57.7M, down from $84.5M.
- FDA approved Emrosi (rosacea) in Nov 2024 and UNLOXCYT (cSCC) in Dec 2024; commercial launch of Emrosi underway.
- Checkpoint to be acquired by Sun Pharma for $4.10/sh upfront plus up to $0.70 CVR; Fortress expects ~$28M at closing plus 2.5% royalty.
- FDA accepted CUTX-101 NDA for priority review with PDUFA date Sept 30, 2025.
- Cash $57.3M as of Dec 31, 2024; paused Series A Preferred dividends in July 2024, deferring ~$0.7M/month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025004154/0001558370-25-004154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000155837025004154/fbio-20250331x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-004154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer